Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Quidel recalls a year’s worth of COVID-19 PCR tests over ‘significant risk’ of false negatives
U.S. vaccine rollout prevented up to 1.25M hospitalizations, 279K additional deaths, study finds
Express Scripts' supply chain lessons learned from COVID-19
New insights into how stem cells shield against RNA viruses could boost COVID-19 R&D
COVID-19 tracker: Single Pfizer, AZ shot may not be enough against Delta; Exscientia bags $1.5M for AI-discovered drugs
Britain bets on biotech as billions set to boost life sciences sector

Featured Story

Quidel recalls a year’s worth of COVID-19 PCR tests over ‘significant risk’ of false negatives

By Andrea Park

The recall covers more than three dozen lots of the test, spanning 18,385 kits, each of which can be used to perform 96 analyses. The affected kits were manufactured between March 2020 and March 2021 and were distributed between mid-March 2020 and the end of May this year.

U.S. vaccine rollout prevented up to 1.25M hospitalizations, 279K additional deaths, study finds

By Robert King

A new study found that the U.S. vaccination campaign prevented up to 1.25 million hospitalizations and 279,000 additional deaths.

Express Scripts' supply chain lessons learned from COVID-19

By Paige Minemyer

As Cigna's Evernoth expands the capabilities under its umbrella, the company is finding new solutions to address waste in the healthcare system.

New insights into how stem cells shield against RNA viruses could boost COVID-19 R&D

By Kyle LaHucik

Researchers at the Francis Crick Institute found that stem cells contain instructions to build a protein called antiviral Dicer, which protects them against SARS-CoV-2 and Zika viruses. They believe their insights could inform efforts to develop new therapies for COVID-19 and other infectious diseases.

COVID-19 tracker: Single Pfizer, AZ shot may not be enough against Delta; Exscientia bags $1.5M for AI-discovered drugs

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

The Delta variant "barely" reacted to a single shot of either Pfizer or AstraZeneca's jab, a new study shows. U.K.-based Exscientia scored $1.5 million to use its artificial intelligence to discover a new class of COVID-19 drugs. And more headlines.

Britain bets on biotech as billions set to boost life sciences sector

By Ben Adams

As the U.K. looks to boost the economy after a major COVID hit—and the looming spotlight of Brexit—the government is creating a new £1 billion public-private partnership in life sciences. British Patient Capital, the commercial arm of the U.K. government’s British Business Bank, is kickstarting the program, funneling £200 million to “specialist funds” designed to “unlock the potential of innovative U.K. life sciences companies so that they can grow their operations and create high-skilled jobs in the U.K.,” according to the government.

COVID-19 Tracker